查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018752

腦腫瘤診斷市場：依技術、產品、適應症、通路和最終用戶分類－2026-2032年全球市場預測

Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦腫瘤診斷市場價值將達到 51.1 億美元，到 2026 年將成長至 57.8 億美元，到 2032 年將達到 118.4 億美元，年複合成長率為 12.76%。

主要市場統計數據
基準年 2025 51.1億美元
預計年份：2026年 57.8億美元
預測年份 2032 118.4億美元
複合年成長率 (%) 12.76%

對影響腦腫瘤診斷現況和近期未來的臨床需求、診斷流程和監管因素進行全面的情勢分析。

本執行摘要對現代腦腫瘤診斷生態系統進行了關鍵分析，重點在於影響診斷實踐的臨床需求、技術趨勢和相關人員。摘要首先獎勵了從症狀出現到組織病理學確診的診斷流程，著重闡述了診斷準確性、時間以及可及性相互交織並影響患者預後的關鍵點。此外，概要還概述了先進影像技術、分子檢測和傳統病理工作流程之間的相互作用，以及這些方法如何整合到多學科臨床路徑中。

影像學、分子診斷和數位病理學領域的創新整合如何重新定義腦腫瘤診斷工作流程、資料整合和臨床決策。

腦腫瘤的診斷格局正經歷著一場變革，影像學、分子分析和數位病理學的融合應用推動了這項變革。磁振造影（MRI）技術和混合成像技術的進步，使得病灶的表徵更加精細，從而能夠更可靠地區分腫瘤的惡性程度和治療相關的改變。同時，次世代定序和標靶PCR技術拓展了可用於診斷和治療方法選擇的分子標記範圍，進而提升了精準診斷在治療方案製定中的作用。

本研究評估了 2025 年關稅和貿易政策調整將如何影響整個腦腫瘤診斷供應鏈的籌資策略、供應商多元化和成本管理。

2025年關稅調整和貿易政策調整的累積影響正在給醫療服務提供者和製造商帶來新的供應鏈和成本壓力，他們必須積極應對。進口設備組件、試劑和影像設備的關稅提高正在改變診斷實​​檢查室和醫院的採購決策，迫使各機構探索替代籌資策略、重新談判供應商合約並建立本地庫存緩衝，以維持臨床服務的連續性。

採用多方面的細分觀點，闡明技術類型、產品類型、臨床適應症、分銷管道和最終用戶如何影響採用趨勢和臨床影響。

深入的市場細分突顯了技術、產品組成、臨床適應症、分銷管道和終端用戶畫像如何共同決定產品需求和市場接受度。從技術角度來看，基因檢測、影像學、分子診斷和病理診斷領域各自提供獨特的價值提案。 CT、MRI 和 PET 等影像學技術指南手術規劃，並提供結構和功能資訊以監測治療反應。分子診斷分為次世代定序和 PCR 方法，提供基因組和轉錄組信息，有助於標靶治療和臨床試驗參與決策；病理工作流程，包括切片檢查分析和組織病理學，將形態學評估與分子數據相結合，仍然是診斷的基礎。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和基礎設施差異影響診斷技術的採用路徑和戰略重點。

區域趨勢對策略至關重要，因為美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、法規環境和醫療基礎設施存在顯著差異。在美洲，擁有完善的報銷體系和大規模研究網路支持的先進三級醫療機構，其特點是積極採用尖端影像和分子診斷技術。這不僅有利於將創新技術快速整合到臨床路徑中，也對具有明確臨床效用的差異化診斷方法提出了更高的競爭要求。

此分析揭示了成熟企業、專業分子診斷公司和敏捷創新者在競爭格局中的定位。

腦瘤診斷領域的競爭格局呈現出多元化的特點，既有成熟的影像診斷設備製造商，也有專注於分子診斷的專業公司，還有新興企業，它們致力於人工智慧影像分析和新型檢測方法。現有影像設備供應商透過配套服務協議和長期維護合約與醫院和神經外科中心保持緊密的合作關係，這雖然導致轉換成本高昂，但也為混合影像和工作流程整合方面的合作創造了機會。分子診斷公司則憑藉其檢測項目的廣度、檢測方法的靈敏度以及針對臨床終點的檢驗來脫穎而出，並且經常與學術機構合作開展前瞻性評估和指南制定工作。

產業領導者需要製定可操作的策略重點，使產品創新、供應鏈韌性和證據產生與臨床部署要求保持一致。

產業領導者應採取三管齊下的策略，在最大限度地發揮臨床影響力的同時，保持商業性韌性：投資於整合影像、分子數據和病理背景的綜合診斷解決方案；透過策略採購和服務模式增強價值鏈韌性；以及建立強大的循證項目，以證明其臨床效用和經濟價值。優先採用綜合解決方案可減少臨床工作流程中的摩擦，並促進與醫療機構建立更深層的合作關係。同時，對維護、培訓和遠端支援的投資可降低停機風險，並提高客戶維繫留存率。

採用嚴謹的混合方法研究方法，結合臨床醫師的直接參與和二手文獻的整合，以檢驗對診斷效能和實施的見解。

本分析整合了對臨床專業人員、檢查室管理人員和行業高管的訪談，以及涵蓋同行評審文獻、監管出版刊物和技術白皮書的二手研究。主要的定性研究深入分析了臨床工作流程、診斷過程挑戰以及醫院和診斷檢查室面臨的實際限制。二手資訊用於驗證技術能力、監管里程碑和公共部門採購趨勢，尤其著重於近期同儕審查的、檢驗診斷績效指標和部署結果的研究。

一份簡潔、全面的分析報告，重點在於將診斷技術的進步轉化為患者療效改善所必需的技術、證據和營運策略的整合。

總之，腦腫瘤診斷領域正朝著整合的、數據豐富的診斷生態系統發展，該系統融合了先進的影像技術、分子譜分析和最佳化的病理工作流程。這一方向為提高診斷準確性和實現個體化治療方法提供了巨大機遇，但要充分發揮這一潛力，需要在技術整合、臨床醫生培訓和循證醫學證據生成方面進行合作投資。同時，不斷變化的貿易趨勢以及監管和報銷環境的區域差異，也要求制定適應性強的商業策略和建構具有韌性的供應鏈。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦腫瘤診斷市場：依技術分類

  • 基因檢測
  • 診斷影像
    • 電腦斷層掃描
    • MRI
    • PET
  • 分子診斷
    • NGS
    • PCR
  • 病理
    • 切片檢查分析
    • 組織病理學

第9章：腦腫瘤診斷市場：依產品分類

  • 耗材和試劑
    • 成套工具
    • 探針和試劑
  • 裝置
    • 診斷系統
    • 影像系統
    • 實驗室設備
  • 服務
    • 維護
    • 培訓支援

第10章：腦腫瘤診斷市場：依適應症分類

  • 星狀細胞瘤
  • 多形性膠質母細胞瘤
  • 腦膜瘤
  • 少突膠質細胞瘤

第11章：腦腫瘤診斷市場：依通路分類

  • 離線
  • 線上

第12章：腦腫瘤診斷市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第13章：腦腫瘤診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：腦腫瘤診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦腫瘤診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腦腫瘤診斷市場

第17章：中國腦腫瘤診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Associated Regional and University Pathologists, Inc.
  • Becton, Dickinson and Company
  • Bristol Myers Squibb Co.
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • General Electric Company
  • Grail, LLC
  • Henry Ford Health
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • NantOmics
  • NeoGenomics Laboratories, Inc.
  • Novocure GmbH
  • Oncologica Limited
  • QIAGEN NV
  • Quibim, SL
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market was valued at USD 5.11 billion in 2025 and is projected to grow to USD 5.78 billion in 2026, with a CAGR of 12.76%, reaching USD 11.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.11 billion
Estimated Year [2026] USD 5.78 billion
Forecast Year [2032] USD 11.84 billion
CAGR (%) 12.76%

Comprehensive situational framing of clinical imperatives, diagnostic pathways, and regulatory drivers shaping the present and near-term future of brain cancer diagnostics

This executive summary introduces a focused analysis of the contemporary brain cancer diagnostics ecosystem, emphasizing clinical needs, technological trajectories, and stakeholder incentives that are shaping diagnostic practice. The narrative begins by framing the diagnostic journey from symptom presentation through to histopathological confirmation, highlighting where diagnostic accuracy, turnaround time, and accessibility intersect to influence patient outcomes. It outlines the interplay between advanced imaging modalities, molecular assays, and traditional pathology workflows, and how these modalities are being integrated into multi-disciplinary care pathways.

The introduction also situates regulatory considerations and reimbursement dynamics as critical enablers or impediments to adoption, noting that regulatory clarity and value-based reimbursement models frequently determine whether innovations transition from research settings into routine clinical use. Finally, the introduction sets expectations for the remainder of the summary: an assessment of transformative shifts, tariff impacts, segmentation insights, regional dynamics, competitive positioning, and practical recommendations to guide strategy for clinicians, diagnostics providers, and investors.

How converging imaging, molecular diagnostics, and digital pathology innovations are redefining diagnostic workflows, data integration, and clinical decision-making for brain tumors

The diagnostic landscape for brain tumors is undergoing a transformative shift driven by convergence across imaging, molecular analysis, and digital pathology. Advances in magnetic resonance imaging protocols and hybrid imaging techniques are refining lesion characterization, enabling more confident distinctions between tumor grades and treatment-related changes. Concurrently, next-generation sequencing and targeted PCR panels are expanding the molecular fingerprints available for diagnosis and therapeutic selection, thereby elevating the role of precision diagnostics in care planning.

These technological developments are accompanied by evolving clinical workflows that prioritize minimally invasive sampling and longitudinal monitoring. Liquid biopsy approaches and improved biopsy targeting through image guidance are reducing procedural risk while increasing the frequency and richness of molecular data available across the patient journey. Moreover, artificial intelligence and machine learning are being deployed to augment image interpretation and histopathology review, accelerating diagnostic turnaround and reducing inter-observer variability. Collectively, these shifts are not merely incremental; they are reconfiguring multidisciplinary care teams, data governance models, and vendor-provider partnerships, and are prompting institutions to reassess capital allocation for diagnostic platforms versus consumables and informatics.

Assessing how 2025 tariff and trade adjustments are reshaping procurement strategies, supplier diversification, and cost management across brain cancer diagnostic supply chains

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced a layer of supply chain and cost pressure that providers and manufacturers must actively manage. Increased duties on imported instrumentation components, reagents, and imaging hardware have altered procurement calculus for diagnostic laboratories and hospitals, leading organizations to explore alternative sourcing strategies, renegotiated supplier contracts, and localized inventory buffers to preserve clinical continuity.

These trade headwinds have also accelerated discussions around supplier diversification and nearshoring for critical reagents and imaging consumables. Diagnostic providers are balancing the short-term implications of higher landed costs against the long-term benefits of supply resilience, often choosing to invest in maintenance and training services to extend equipment lifecycle performance. At the same time, some manufacturers have reacted by adjusting product portfolios and packaging to mitigate tariff exposure, or by increasing engagement with regulatory authorities and payer stakeholders to demonstrate clinical value propositions that justify higher reimbursement to offset increased operational expense. The net result is a marketplace where procurement strategies, contracting agility, and operational contingency planning have become as important as clinical differentiation.

A multidimensional segmentation perspective revealing how technology types, product categories, clinical indications, distribution channels, and end users shape adoption and clinical impact

Insightful segmentation underscores how technology, product composition, clinical indication, distribution channels, and end-user profiles jointly determine product demand and adoption pathways. When the market is considered by technology, genetic testing, imaging, molecular diagnostics, and pathology each contribute distinct value propositions: imaging modalities such as CT, MRI, and PET provide structural and functional insights that guide surgical planning and monitor response; molecular diagnostics, split into next-generation sequencing and PCR approaches, deliver genomic and transcriptomic context that informs targeted therapies and clinical trial enrollment; pathology workflows encompassing biopsy analysis and histopathology remain the diagnostic anchor, integrating morphological assessment with ancillary molecular data.

Viewed through the lens of product types, consumables and reagents including kits and probes enable much of the molecular testing throughput, while diagnostic systems, imaging systems, and lab instruments form the capital infrastructure that dictates testing capacity and throughput. Services such as equipment maintenance, training, and technical support are critical to sustaining diagnostic quality and uptime. Considering clinical indications, diagnostic needs differ across tumor classes including astrocytoma, glioblastoma multiforme, meningioma, and oligodendroglioma; glioblastoma multiforme cases often demand rapid, multimodal diagnostics for aggressive treatment planning, whereas meningioma evaluation may rely more heavily on imaging characteristics and surgical pathology. Distribution channel dynamics reveal that offline relationships remain essential for complex installations and clinician engagement, while online channels are increasingly influential for consumables procurement and information dissemination. Finally, end-user segmentation shows divergent priorities: diagnostic laboratories emphasize throughput, validation, and compliance; hospitals prioritize integrated workflows and multidisciplinary coordination; research institutes prioritize analytical flexibility and assay development capacity. Understanding how these segments interact clarifies where innovation investments and commercial efforts will yield the strongest clinical and economic returns.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption pathways and strategic priorities for diagnostics

Regional dynamics are central to strategy because clinical practice patterns, regulatory environments, and healthcare infrastructure vary substantially across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems tend to feature advanced tertiary centers with high adoption of cutting-edge imaging and molecular diagnostics, supported by established reimbursement mechanisms and sizable research networks. This enables rapid translation of innovations into clinical pathways but also creates competitive pressure for differentiated diagnostics that demonstrate clear clinical utility.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous reimbursement environments prompt vendors to pursue country-level strategies, often partnering with regional distributors and academic centers to validate clinical and economic value. Meanwhile, Asia-Pacific presents a mix of high-growth urban health systems and resource-constrained settings; large academic hospitals and research institutes in major markets drive adoption of NGS and advanced imaging, while other areas prioritize cost-effective, scalable diagnostics and robust supply chain solutions. Across these regions, the interplay between local clinical practice, infrastructure readiness, and commercial models dictates where manufacturers should prioritize investments in training, service networks, and evidence generation to support uptake.

Competitive landscape dynamics revealing how incumbents, specialized molecular firms, and agile innovators are positioning through partnerships, evidence, and service offerings

Competitive landscapes in brain cancer diagnostics are characterized by a mix of established imaging and laboratory instrument manufacturers, specialized molecular diagnostics firms, and emerging players focused on AI-driven interpretation or novel assay chemistries. Incumbent imaging vendors maintain strong relationships with hospitals and neurosurgical centers through bundled service agreements and long-term maintenance contracts, which creates high switching costs but also opens opportunities for partnerships on hybrid imaging and workflow integration. Molecular diagnostics companies differentiate through panel breadth, assay sensitivity, and validation against clinical endpoints, often collaborating with academic centers for prospective evaluation and guideline inclusion.

Smaller innovators are carving niche positions with single-analyte tests or AI algorithms that augment radiological and pathological interpretation, and they often seek co-development or licensing agreements with larger manufacturers to scale distribution. Across the competitive spectrum, companies that align their offerings with clinician workflows, provide robust real-world evidence, and support implementation through training and service are most likely to secure sustained adoption. Strategic alliances, technology licensing, and targeted acquisitions remain the primary routes by which market participants expand capabilities and geographic reach.

Actionable strategic priorities for industry leaders to align product innovation, supply chain resilience, and evidence generation with clinical adoption imperatives

Industry leaders should pursue a three-pronged approach to maximize clinical impact while preserving commercial resilience: invest in integrated diagnostic solutions that combine imaging, molecular data, and pathologic context; strengthen supply chain resilience through strategic sourcing and service models; and build robust evidence generation programs that demonstrate clinical utility and economic value. Prioritizing integrated solutions reduces friction in clinical workflows and fosters deeper institutional relationships, while investment in maintenance, training, and remote support mitigates downtime risk and enhances customer retention.

In parallel, companies should adopt flexible commercial models that accommodate both centralized laboratory workflows and point-of-care testing paradigms, enabling penetration across hospital systems and specialized diagnostic laboratories. Evidence generation must include prospective clinical validation and health-economic analyses that resonate with payers and hospital procurement committees. Finally, cultivating partnerships with academic centers and patient advocacy groups accelerates access to clinical cohorts for validation and increases the likelihood of guideline adoption and clinician endorsement.

Rigorous mixed-method research approach combining primary clinician engagement and secondary literature synthesis to validate diagnostic performance and implementation insights

This analysis synthesizes primary interviews with clinical experts, laboratory directors, and industry executives, together with secondary research across peer-reviewed literature, regulatory publications, and technology white papers. Primary qualitative engagements informed perspectives on clinical workflows, pain points in diagnostic pathways, and practical constraints faced by hospitals and diagnostic laboratories. Secondary sources were used to triangulate technology capabilities, regulatory milestones, and public sector procurement trends, with particular attention to recent peer-reviewed studies that validate diagnostic performance metrics and implementation outcomes.

Data integrity was reinforced through a multi-layered validation process that included cross-verification of technological attributes with manufacturer technical specifications and consultation with independent clinical pathologists. Limitations and potential biases were addressed by sampling across geographies and facility types, and by documenting areas where empirical evidence remains nascent, such as clinical utility for certain emerging liquid biopsy approaches. Wherever possible, conclusions prioritize reproducible clinical findings and consensus viewpoints from experienced practitioners to ensure the analysis is actionable and grounded in clinical reality.

Concise synthesis emphasizing the integration of technology, evidence, and operational strategy needed to translate diagnostic advances into improved patient outcomes

In conclusion, the brain cancer diagnostics arena is transitioning toward integrated, data-rich diagnostic ecosystems that combine advanced imaging, molecular profiling, and enhanced pathology workflows. This trajectory offers meaningful opportunities to improve diagnostic precision and to personalize treatment selection, but realizing that potential requires coordinated investments in technology integration, clinician training, and evidence generation. At the same time, evolving trade dynamics and regional variations in regulatory and reimbursement environments necessitate adaptive commercial strategies and resilient supply chains.

Decision-makers should therefore focus on enabling interoperability across modalities, supporting clinical adoption with compelling real-world evidence, and designing flexible delivery models that accommodate diverse institutional needs. By aligning technological innovation with pragmatic implementation pathways and payer engagement, stakeholders can accelerate the translation of diagnostic advances into improved patient outcomes while maintaining operational and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Diagnostics Market, by Technology

  • 8.1. Genetic Testing
  • 8.2. Imaging
    • 8.2.1. CT Scan
    • 8.2.2. MRI
    • 8.2.3. PET
  • 8.3. Molecular Diagnostics
    • 8.3.1. NGS
    • 8.3.2. PCR
  • 8.4. Pathology
    • 8.4.1. Biopsy Analysis
    • 8.4.2. Histopathology

9. Brain Cancer Diagnostics Market, by Product

  • 9.1. Consumables & Reagents
    • 9.1.1. Kits
    • 9.1.2. Probes & Reagents
  • 9.2. Equipment
    • 9.2.1. Diagnostic Systems
    • 9.2.2. Imaging Systems
    • 9.2.3. Lab Instruments
  • 9.3. Services
    • 9.3.1. Maintenance
    • 9.3.2. Training & Support

10. Brain Cancer Diagnostics Market, by Indication

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma Multiforme
  • 10.3. Meningioma
  • 10.4. Oligodendroglioma

11. Brain Cancer Diagnostics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Brain Cancer Diagnostics Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Brain Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Cancer Diagnostics Market

17. China Brain Cancer Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Associated Regional and University Pathologists, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bristol Myers Squibb Co.
  • 18.10. Canon Medical Systems Corporation
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. General Electric Company
  • 18.14. Grail, LLC
  • 18.15. Henry Ford Health
  • 18.16. Hitachi, Ltd.
  • 18.17. Hologic, Inc.
  • 18.18. Illumina, Inc.
  • 18.19. Invitae Corporation
  • 18.20. Koninklijke Philips N.V.
  • 18.21. Laboratory Corporation of America Holdings
  • 18.22. NantOmics
  • 18.23. NeoGenomics Laboratories, Inc.
  • 18.24. Novocure GmbH
  • 18.25. Oncologica Limited
  • 18.26. QIAGEN N.V.
  • 18.27. Quibim, S.L.
  • 18.28. Siemens Healthineers AG
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 252. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 264. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)